Spectral domain-optical coherence tomographic findings in patients with ankylosing spondylitis under anti-tumor necrosis factor-alpha therapy

References

• Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol 1995;5:392–399
   PubMed Web of Science ®Google Scholar
• Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001;19:163–196
   PubMed Web of Science ®Google Scholar
• Gruss HJ. Molecular, structural, and biological characteristics of the tumor necrosis factor ligand superfamily. Int J Clin Lab Res 1996;26:143–159
   PubMedGoogle Scholar
• Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007;369:1379–1390
   PubMed Web of Science ®Google Scholar
• Braun J, Sieper J. Biological therapies in the spondyloarthritides – the current state. Rheumatology (Oxford) 2004;43:1072–1084
   PubMed Web of Science ®Google Scholar
• Schuman JS, Hee MR, Arya AV, et al. Optical coherence tomography: a new tool for glaucoma diagnosis. Curr Opin Ophthalmol 1995;6:89–95
   PubMedGoogle Scholar
• Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286–2291
   PubMed Web of Science ®Google Scholar
• Gorman JD, Sack KE, Davis JC Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002;346:1349–1356
   PubMed Web of Science ®Google Scholar
• Braun J, van der Heijde D. Novel approaches in the treatment of ankylosing spondylitis and other spondyloarthritides. Expert Opin Investig Drugs 2003;12:1097–1109
   PubMed Web of Science ®Google Scholar
• Ruof J, Stucki G. Validity aspects of erythrocyte sedimentation rate and C-reactive protein in ankylosing spondylitis: a literature review. J Rheumatol 1999;26:966–970
   PubMed Web of Science ®Google Scholar
• Spoorenberg A, van der Heijde D, de Klerk E, et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999;26:980–984
   PubMed Web of Science ®Google Scholar
• Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. Joint Bone Spine 2007;74:249–253
   PubMed Web of Science ®Google Scholar
• Sawada H, Fukuchi T, Tanaka T, Abe H. Tumor necrosis factor-alpha concentrations in the aqueous humor of patients with glaucoma. Invest Ophthalmol Vis Sci 2010;51:903–906
   PubMed Web of Science ®Google Scholar
• Huang P, Qi Y, Xu YS, et al. Serum cytokine alteration is associated with optic neuropathy in human primary open angle glaucoma. J Glaucoma 2010;19:324–330
   PubMed Web of Science ®Google Scholar
• Tezel G, Li LY, Patil RV, Wax MB. TNF-alpha and TNF-alpha receptor-1 in the retina of normal and glaucomatous eyes. Invest Ophthalmol Vis Sci 2001;42:1787–1794
   PubMed Web of Science ®Google Scholar
• Tezel G, Wax MB. Increased production of tumor necrosis factor-alpha by glial cells exposed to simulated ischemia or elevated hydrostatic pressure induces apoptosis in cocultured retinal ganglion cells. J Neurosci 2000;20:8693–8700
   PubMed Web of Science ®Google Scholar
• Nakazawa T, Nakazawa C, Matsubara A, et al. Tumor necrosis factor-alpha mediates oligodendrocyte death and delayed retinal ganglion cell loss in a mouse model of glaucoma. J Neurosci 2006;26:12633–12641
   PubMed Web of Science ®Google Scholar
• Mirshahi A, Hoehn R, Lorenz K, et al. Anti-tumor necrosis factor alpha for retinal diseases: current knowledge and future concepts. J Ophthalmic Vis Res 2012;7:39–44
   PubMedGoogle Scholar
• Diaz-Llopis M, García-Delpech S, Salom D, et al. Adalimumab therapy for refractory uveitis: a pilot study. J Ocul Pharmacol Ther 2008;24:351–361
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Theodossiadis PG, Pantelia E, et al. Infliximab for chronic cystoid macular edema associated with uveitis. Am J Ophthalmol 2004;138:648–650
   PubMed Web of Science ®Google Scholar
• Fukuda K, Kumagai N, Nakamura H, et al. Successful treatment of cystoid macular edema with etanercept in a patient with rheumatoid arthritis associated panuveitis. Nihon Ganka Gakkai Zasshi 2008;112:51–57
   PubMedGoogle Scholar
• Sfikakis PP, Grigoropoulos V, Emfietzoglou I, et al. Infliximab for diabetic macular edema refractory to laser photocoagulation: a randomized, double-blind, placebo-controlled, crossover, 32-week study. Diabetes Care 2010;33:1523–1528
   PubMed Web of Science ®Google Scholar
• Markomichelakis NN, Theodossiadis PG, Sfikakis PP. Regression of neovascular age-related macular degeneration following infliximab therapy. Am J Ophthalmol 2005;139:537–540
   PubMed Web of Science ®Google Scholar
• Wu L, Hernandez-Bogantes E, Roca JA, et al. Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina 2011;31:298–303
   PubMed Web of Science ®Google Scholar
• Wu L, Arevalo JF, Hernandez-Bogantes E, et al. Intravitreal tumor necrosis factor-alpha inhibitors for neovascular age-related macular degeneration suboptimally responsive to antivascular endothelial growth factor agents: a pilot study from the Pan American Collaborative Retina Study Group. J Ocul Pharmacol Ther 2013;29:366–371
   PubMed Web of Science ®Google Scholar
• Wu L, Arevalo JF, Hernandez-Bogantes E, Roca JA. Intravitreal infliximab for refractory pseudophakic cystoid macular edema: results of the Pan-American Collaborative Retina Study Group. Int Ophthalmol 2012;32:235–243
   PubMedGoogle Scholar
• Lumbroso B, Rispoli M. Pratical handbook of OCT. New Delhi: Jaypee Brothers Medical Publishers; 2012. p. 3
   Google Scholar
• Tan BB, Natividad M, Chua KC, Yip LW. Comparison of retinal nerve fiber layer measurement between 2 spectral domain OCT instruments. J Glaucoma 2012;21:266–273
   PubMed Web of Science ®Google Scholar
• Dogra S, Khullar G. Tumor necrosis factor-α antagonists: side effects and their management. Indian J Dermatol Venereol Leprol 2013;79:S35–S46
   PubMed Web of Science ®Google Scholar
• Theodossiadis PG, Markomichelakis NN, Sfikakis PP. Tumor necrosis factor antagonists: preliminary evidence for an emerging approach in the treatment of ocular inflammation. Retina 2007;27:399–413
   PubMed Web of Science ®Google Scholar
• Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 2010;35:751–756
   PubMed Web of Science ®Google Scholar
• Wang F, Wang NS. Etanercept therapy-associated acute uveitis: a case report and literature review. Clin Exp Rheumatol 2009;27:838–839
   PubMed Web of Science ®Google Scholar
• Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 2007;56:3248–3252
   PubMed Web of Science ®Google Scholar